The reactive organoselenium compound ebselen is being investigated for treatment of coronavirus disease 2019 (COVID-19) and other diseases. We report structure-activity studies on sulfur analogues of ebselen with the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) main protease (M ), employing turnover and protein-observed mass spectrometry-based assays. The results reveal scope for optimisation of ebselen/ebselen derivative- mediated inhibition of M , particularly with respect to improved selectivity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9015279 | PMC |
| http://dx.doi.org/10.1002/cmdc.202100582 | DOI Listing |
Publication Analysis
Top Keywords
structure-activity studies
8
reveal scope
8
scope optimisation
8
sars-cov-2 main
8
main protease
8
studies reveal
4
optimisation ebselen-type
4
ebselen-type inhibition
4
inhibition sars-cov-2
4
protease reactive
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!